港股异动 | 春立医疗(1858.HK)再升超7% 股价续创新高
格隆汇9月2日丨春立医疗(01858.HK)近期持续拉升,股价续创新高。现再升7.3%,报29.4港元,暂成交946.82万港元,最新总市值4067亿港元。春立医疗(01858.HK)日前公布,公司中期纯利升116.62%至1.09亿元,营业收入人民币3.75亿元(单位下同),同比增长75.93%。营业收入增长主要是由于关节假体产品销量的增长及销售网络的扩张所致。近期公司收到国家药品监督管理局颁发的“不可吸收带线锚钉”注册证,标志着公司已经进入运动医学领域。业内人士称,公司是国产骨科植入物龙头,陶瓷关节迎爆发周期。老龄化、治疗意识提高和国内医疗器械政策推进之下,看好骨科植入物特别是关节植入行业的发展。未来公司业绩将保持持续较快增长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.